| Literature DB >> 24381714 |
Abstract
Reactive oxygen species (ROS) are cellular signals generated ubiquitously by all mammalian cells, but their relative unbalance triggers also diseases through intracellular damage to DNA, RNA, proteins, and lipids. NADPH oxidases (NOX) are the only known enzyme family with the sole function to produce ROS. The NOX physiological functions concern host defence, cellular signaling, regulation of gene expression, and cell differentiation. On the other hand, increased NOX activity contributes to a wide range of pathological processes, including cardiovascular diseases, neurodegeneration, organ failure, and cancer. Therefore targeting these enzymatic ROS sources by natural compounds, without affecting the physiological redox state, may be an important tool. This review summarizes the current state of knowledge of the role of NOX enzymes in physiology and pathology and provides an overview of the currently available NADPH oxidase inhibitors derived from natural extracts such as polyphenols.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24381714 PMCID: PMC3863456 DOI: 10.1155/2013/271602
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
NOX isoforms and pathology [modified from [22, 23]].
| Characteristic | Binding partners | Intracellular localization | Tissue distribution | Implication in pathology |
|---|---|---|---|---|
| NOX1 | p22phox, NOXO1, NoxA1, Rac1, PDI, TKS4/5* | Caveolae on the plasma membrane, redoxisomes | Colon epithelia VSMCs, endothelial cells, uterus, placenta, prostate, osteoclasts, retinal pericytes, neurons, astrocytes, microglia | Colon cancer, prostate cancer, gastrointestinal inflammation, hypertension, restenosis after angioplasty |
| NOX2 | p22phox, p67phox, p40phox, p47phox, Rac1/2 | Phagosomes, cytoskeleton, lamellipodia, redoxisomes | Phagocytes, CNS, endothelium, VSMCs, fibroblasts, cardiomyocytes, skeletal muscle, hepatocytes, hematopoietic stem cells | Gastrointestinal inflammation, hypertension, myocardial injury, restenosis after angioplasty, melanoma, diabetes, neurodegenerative diseases |
| NOX3 | p22phox, NOXO1 | Plasma membrane | Inner ear, lung endothelial cells, fetal tissues | Hearing loss, pancreatic cancer |
| NOX4 | p22phox, PDI, TKS4/5, Poldip2* | Focal adhesions, nucleus, endoplasmic reticulum, mitochondria | Ubiquitously expressed but highly in the kidney | Pancreatic cancer, melanoma, diabetes |
| NOX5 | Ca2+, Hsp90, CaM# | Internal membranes, plasma membrane | Lymphatic tissue, testis, VSMCs, endothelial cells, spleen, uterus, and prostate | Atherosclerosis prostate cancer, pancreatic cancer |
| Duox1 | Ca2+, DuoxA1 | Plasma membrane | Thyroid, respiratory epithelium | Thyroid dysfunction, cystic fibrosis |
| Duox2 | Ca2+, DuoxA2 | Plasma membrane | Airway epithelial, colon, salivary gland | Thyroid dysfunction, cystic fibrosis |
*Recently, the protein polymerase (DNA-directed) delta-interacting protein 2 (Poldip2) was identified to bind and to increase the activity of NOX4. Further, protein disulfide isomerase (PDI) and a p47phox analogue tyrosine kinase substrate with 4/5 SH3 domains (Tks4/5) have been reported to bind and activate NOX1 and NOX4. NOX4 is the only isoform that produces hydrogen peroxide instead of superoxide.
#The NOX5 protein contains four N-terminal calcium-binding sites that regulate activation of the enzyme. Activity of NOX5 can be further supported by the binding of Hsp90 or Calmodulin to the C-terminus of the protein.
NOX inhibitors.
| Name and origin | Mechanism of action | NOX isoform selectivity | Other pharmacological effects | References |
|---|---|---|---|---|
| AEBSF | Inhibits p47phox assembly with oxidase subunit | NOX2 | Proteases inhibitor | [ |
| Apocynin | Inhibits p47phox assembly with membrane | NOX2 | H2O2 scavenging | [ |
| Berberine | Inhibition of gp91phox expression | NOX2 | Enhancement of SOD activity | [ |
| Blueberry derived polyphenols | Disrupts NOX assembly in lipid rafts | NOX2 | Minimal if any ROS scavenging capacity | [ |
| Celastrol | Inhibition of association between cytosolic subunits and the membrane subunit | Mostly Nox1 and NOX2 | None reported | [ |
| DPI | Flavoprotein inhibitor | No selectivity | Inhibits NOS, xanthine oxidase, NADH ubiquinone oxidoreductase, NADH dehydrogenase, cytocrome P450 oxidoreducatese | [ |
| EGCG | Inhibits the expression of NADPH oxidase subunits | No selectivity | ROS scavenging capacity and ENOX proteins function as terminal oxidases of plasma membrane electron transport (PMET) | [ |
| Emodin | NADPH oxidase p47phox activation | NOX2? | Interfere with electron transport process and in altering cellular redox status | [ |
| Ginko biloba | Inhibition of Rac1- and p47phox-mediated NADPH oxidase activation | NOX2? | Increases the expression of Cu-Zn superoxide dismutase heat shock protein 70 | [ |
| HDMPPA | Downregulates expression of p47phox and Rac1 | NOX2? | Preservation of NO bioavailability | [ |
| Magnolol and honokiol | Inhibit ERK pathway | unknown | Inhibit NO production | [ |
| Plumbagin | Unknown | Nox4 | ROS scavenger | [ |
| Prodigiosin | Inhibits the binding of p47phox and Rac to the membrane components | NOX2? | Reduces gp91(phox) and iNOS expression | [ |
| Resveratrol | Decreases NADPH oxidase expression (p47phox) | NOX2? | Free-radicals-scavenging | [ |
| S17834 | Unknown | NOX2 NOX4 | None reported | [ |
| Sinomenine | Inhibits p47phox translocation to the cell membrane | NOX2? | Minimal interaction with opiate receptors | [ |